Has Crystal Ball received payments from drug or device companies?

Yes. Drug and device makers reported $2,511 in general payments to Crystal Ball across 127 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Crystal Ball did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Crystal Ball come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Crystal Ball

Family · Dungannon, VANPI 1053863688

Payments from drug & device makers

$2,511in general payments, 2019–2025

Across 127 payments — averaging $19.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Abbott$961
AstraZeneca$453
AbbVie$307
Lilly USA, LLC$190
Novo Nordisk$150
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$79
plus $371 from 12 others

What the payments were for

Food & beverage$2,511100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Abbott	52	$961
AstraZeneca	11	$453
AbbVie	15	$307
Lilly USA, LLC	11	$190
Novo Nordisk	10	$150
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	5	$79
Inogen, Inc.	6	$76
Biohaven Pharmaceutical Holding Company Ltd.	3	$53
Exact Sciences	2	$40
Dexcom, Inc.	1	$38
Bayer	2	$35
Pfizer	2	$29
GSK	2	$24
Novartis	1	$19
Insulet Corporation	1	$16
Amarin Pharma, Inc.	1	$15
Sanofi-aventis U.S. LLC	1	$14
Impel Pharmaceuticals Inc.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,511 in reported general payments places this provider in the 85th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
FarxigaDapagliflozin Propanediol	21	$29,648
TrulicityDulaglutide	14	$26,002
EliquisApixaban	24	$23,128
Breztri AerosphereBudesonide/Glycopyr/Formoterol	16	$15,242
Tresiba Flextouch U-100Insulin Degludec	14	$6,772
Albuterol Sulfate HfaAlbuterol Sulfate	29	$1,398
Omeprazole	87	$1,285
Buspirone Hcl	36	$691
Losartan Potassium	81	$683
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	31	$672
FenofibrateFenofibrate Nanocrystallized	15	$468
Metoprolol Succinate	42	$445
Oxycodone Hcl	25	$438
Famotidine	24	$425
Duloxetine Hcl	21	$406

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere	$453	$44,89037 claims
Lilly USA, LLCTrulicity	$190	$26,00214 claims
PfizerEliquis	$29	$23,12824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,332 family providers in Virginia.

Other family in Dungannon

Andrea CottonVirginia Beach$696K
Susan MooreWytheville$438K
Ellen WermterCharlottesville$251K
Dana StallingsFranklin$225K
Jocelyn BrackettHerndon$199K
Hochong Smith GillesRichmond$131K
Sean OlaughlinMidlothian$110K
Adam MedlinHampton$67K
Casey SharpDanville$63K
Norman JacobowitzManassas$55K

See the full list for Virginia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →